Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
J Mol Diagn. 2011 Nov;13(6):669-77. doi: 10.1016/j.jmoldx.2011.07.002. Epub 2011 Aug 30.
Alterations of BRAF are the most common known genetic aberrations in pediatric gliomas. They frequently are found in pilocytic astrocytomas, where genomic duplications involving BRAF and the poorly characterized gene KIAA1549 create fusion proteins with constitutive B-Raf kinase activity. BRAF V600E point mutations are less common and generally occur in nonpilocytic tumors. The development of BRAF inhibitors as drugs has created an urgent need for robust clinical assays to identify activating lesions in BRAF. KIAA1549-BRAF fusion transcripts have been detected in frozen tissue, however, methods for FFPE tissue have not been reported. We developed a panel of FFPE-compatible quantitative RT-PCR assays for the most common KIAA1549-BRAF fusion transcripts. Application of these assays to a collection of 51 low-grade pediatric gliomas showed 97% sensitivity and 91% specificity compared with fluorescence in situ hybridization or array comparative genomic hybridization. In parallel, we assayed samples for the presence of the BRAF V600E mutation by PCR pyrosequencing. The data further support previous observations that these two alterations of the BRAF, KIAA1549 fusions and V600E point mutations, are associated primarily with pilocytic astrocytomas and nonpilocytic gliomas, respectively. These results show that fusion transcripts and mutations can be detected reliably in standard FFPE specimens and may be useful for incorporation into future studies of pediatric gliomas in basic science or clinical trials.
BRAF 改变是儿科胶质瘤中最常见的已知遗传异常。它们经常在毛细胞星形细胞瘤中发现,其中涉及 BRAF 和特征不明确的基因 KIAA1549 的基因组重复产生具有组成型 B-Raf 激酶活性的融合蛋白。BRAF V600E 点突变较少见,通常发生在非毛细胞肿瘤中。BRAF 抑制剂作为药物的发展迫切需要强大的临床检测方法来识别 BRAF 中的激活病变。已经在冷冻组织中检测到 KIAA1549-BRAF 融合转录本,然而,尚未报道用于 FFPE 组织的方法。我们开发了一组适用于最常见的 KIAA1549-BRAF 融合转录本的 FFPE 兼容定量 RT-PCR 检测方法。将这些检测方法应用于 51 例低级别儿科胶质瘤的集合中,与荧光原位杂交或阵列比较基因组杂交相比,其敏感性为 97%,特异性为 91%。同时,我们通过 PCR 焦磷酸测序检测样本中是否存在 BRAF V600E 突变。这些数据进一步支持了先前的观察结果,即 BRAF 的这两种改变,KIAA1549 融合和 V600E 点突变,分别主要与毛细胞星形细胞瘤和非毛细胞神经胶质瘤相关。这些结果表明,融合转录本和突变可以在标准 FFPE 标本中可靠地检测到,可能对纳入未来儿科胶质瘤的基础科学或临床试验研究有用。